SCHEMBL248223

SCHEMBL248223

[2H]C([2H])([2H])C(c1cc2nnc(-c3cc(F)ccc3F)n2nc1Cl)(C([2H])([2H])[2H])C([2H])([2H])[2H]

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.49
GABRG2 P18507 2/20 0.49
GABRB3 P28472 2/20 0.49
GABRA5 P31644 2/20 0.49
GABRA3 P34903 2/20 0.49
GABRA2 P47869 2/20 0.49
HSD11B1 P28845 4/20 0.33
MAPK14 Q16539 2/20 0.32
KDM4E B2RXH2 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PDE2A O00408 1/20 0.31
PDE10A Q9Y233 1/20 0.31
BCHE P06276 1/20 0.31
DPP4 P27487 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16625049 0.97 GABRA1 (0.51) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL248720 0.92 GABRG2 (0.57) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6524041 0.87 GABRA1 (0.47) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12794057 0.84 GABRA1 (0.48) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL2656762 0.78 GABRA1 (0.54) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6527771 0.76 GABRA1 (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL12794117 0.75 GABRA1 (0.45) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL248220 0.75 GABRG2 (0.82) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29528203 0.75 GABRG2 (0.88) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL248296 0.75 GABRG2 (0.88) GABRA1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150158870-A1 POLYMORPHS OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE CONCERT PHARMACEUTICALS INC. 2015-06-11 US disclosed
US-20150119398-A1 FORM 2 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE CONCERT PHARMACEUTICALS INC. 2015-04-30 US disclosed
US-20150099753-A1 FORM 5 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE CONCERT PHARMACEUTICALS INC. 2015-04-09 US disclosed
US-8921366-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2014-12-30 US disclosed
US-20130225590-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES CONCERT PHARMACEUTICALS, INC. (US) 2013-08-29 US disclosed
US-8399467-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS, INC. (US) 2013-03-19 US disclosed
US-20120004236-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES CONCERT PHARMACEUTICALS INC. (US) 2012-01-05 US disclosed
US-8003646-B2 Substituted triazolo-pyridazine derivatives CONCERT PHARMACEUTICALS INC. (US) 2011-08-23 US disclosed
US-20100056529-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES CONCERT PHARMACEUTICALS INC. (US) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004236-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES GABRA5, GABRA2, GABRA3 GABRA1 4/4885GABRG2 17/4885GABRB3 7/4885
US-20150158870-A1 POLYMORPHS OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE TAF9, TERT, TFDP2 GABRA1 4504/4885GABRG2 4439/4885GABRB3 4526/4885
US-20150119398-A1 FORM 2 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE TTI2, TTR, RIF1 GABRA1 3410/4885GABRG2 3433/4885GABRB3 3083/4885
US-20100056529-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES GABRA5, GABRA2, GABRA3 GABRA1 4/4885GABRG2 17/4885GABRB3 7/4885
US-20150099753-A1 FORM 5 POLYMORPH OF 7-(TERT-BUTYL-D9)-3-(2,5-DIFLUOROPHENYL)-6-((1-METHYL-1H-1,2,4-TRIAZOL-5-YL)METHOXY)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE RIF1, TTR, TERT GABRA1 4349/4885GABRG2 4165/4885GABRB3 4156/4885
US-20130225590-A1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES GABRA5, GABRA2, GABRA3 GABRA1 4/4885GABRG2 17/4885GABRB3 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.